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Summary
 
L-selectin mediates leukocyte rolling on vascular endothelium during inflammation. Although
vascular endothelium can be activated with inflammatory cytokines to express functional L-selec-
tin ligands, these ligands have not been well characterized. In this study, fucosyltransferase VII
cDNA (Fuc-TVII) transfection of the EA.hy926 human vascular endothelial cell line (926-
 
FtVII) induced functional L-selectin ligand expression and expression of sialyl Lewis
 
x
 
 (sLe
 
x
 
), as
defined by HECA-452 (cutaneous lymphocyte antigen; CLA) and CSLEX-1 mAbs. Cytokine
activation of human umbilical vein endothelial cells (HUVEC) also induced functional L-selec-
tin ligand expression, with increased CLA expression and Fuc-TVII transcription. The majority
of L-selectin–dependent lymphocyte attachment to activated HUVEC and 926-FtVII cells was
blocked specifically by treating the endothelial cells with the HECA-452 mAb, but not the
CSLEX-1 mAb. CLA-bearing ligands on vascular endothelium also required sulfation and ap-
propriate molecular scaffolds for functional activity, but were distinct from the L-selectin ligands
previously identified by the MECA-79 mAb. These findings demonstrate that the HECA-452–
defined antigen, CLA, is an essential carbohydrate component of vascular L-selectin ligands. 
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L
 
-selectin mediates lymphocyte binding to high endo-
thelial venules (HEV)
 
1
 
 of peripheral lymph nodes, and
facilitates leukocyte rolling along vascular endothelium
during immune or inflammatory responses (1, 2). L-selectin
is constitutively expressed by most leukocytes, whereas
other members of the selectin family, P- and E-selectin, are
expressed by activated vascular endothelium. The selectins
bind carbohydrate determinants displayed in the proper
context on a limited number of glycoproteins or proteogly-
cans, which serve as specific scaffolds for the display of oli-
gosaccharides recognized by the selectin lectin/epidermal
growth factor–like domains. L-selectin binds to at least four
different heavily glycosylated mucin-like proteins expressed
by HEV: GlyCAM-1 (3), CD34 (4), MAdCAM-1 (5), and
a 200,000 
 
M
 
r
 
 ligand (6). L-selectin also binds P-selectin
glycoprotein ligand-1 (PSGL-1) expressed by leukocytes
(7–10). Although the complete repertoire of L-selectin
ligands is yet to be defined, most bear sulfated, sialylated,
and fucosylated O-linked carbohydrate side chains which
are essential for L-selectin binding (2).
Prototype carbohydrate ligands for the selectins include
the sialyl Lewis
 
x
 
 (sLe
 
x
 
) tetrasaccharide. Lymph node HEV
express sLe
 
x
 
 (11, 12), although sLe
 
x
 
 expression alone is gen-
erally not sufficient for L-selectin binding (13). L-selectin
ligands expressed by HEV also characteristically require sul-
fation (6, 14) and bear a sulfate-dependent carbohydrate
epitope identified by the MECA-79 mAb that inhibits
lymphocyte binding to peripheral lymph nodes (15, 16).
Sialylation and fucosylation of appropriate carbohydrate
determinants are also critical for L-selectin ligand genera-
tion (17). Fucosyltransferase-VII (Fuc-TVII) is dominant in
generating selectin ligands as illustrated by Fuc-TVII–defi-
cient mice which are characterized by a severe selectin
ligand deficiency resulting in blood leukocytosis, impaired
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Abbreviations used in this paper:
 
 CLA, cutaneous lymphocyte antigen; Fuc-
TVII, fucosyltransferase-VII; 926-FtVII, EA.hy926 cells stably transfected
with Fuc-TVII cDNA; HEV, high endothelial venules; HUVEC, human
umbilical vein endothelial cells; L
 
9
 
IgM, human L-selectin–mouse IgM
fusion protein; OSGE, 
 
O
 
-sialoglycoprotease; PSGL-1, P-selectin glyco-
protein ligand-1; sLe
 
x
 
, sialyl Lewis
 
x
 
. 
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leukocyte extravasation during inflammation, and faulty
lymphocyte migration (18). The specific localization of
Fuc-TVII expression to HEV also correlates with L-selec-
tin ligand expression (19). A specific subset of anti-sLe
 
x
 
mAbs, including HECA-452, 2F3, and 2H5, but not other
anti-sLe
 
x
 
 mAbs such as CSLEX-1 and FH6, recognize sLe
 
x
 
determinants and putative L-selectin ligands found on HEV
(12, 20). The 2H5 mAb blocks L-selectin–dependent bind-
ing of leukocytes to HEV and inflamed skin venules in rats
(21), and the HECA-452 mAb identifies a sLe
 
x
 
-like deter-
minant termed the cutaneous lymphocyte antigen (CLA)
(22–25). Antigen binding by the 2H5 and HECA-452
mAbs is independent of sulfation, but requires both sialic
acid and fucose. By contrast, the MECA-79 mAb defines
sulfate-dependent, but Fuc-TVII– and sialic acid–indepen-
dent, carbohydrate antigens. Although some structures rec-
ognized by the HECA-452 and 2H5 mAbs have been iden-
tified (20), the precise structural specificity of their ligands
has not been defined. Therefore, L-selectin ligands on
HEV are likely to be synthesized through the concerted
action of sialyltransferases, Fuc-TVII, and appropriate sul-
fotransferase(s).
A critical issue remaining is the identity of the vascular
endothelial L-selectin ligand expressed at sites of inflamma-
tion. A cytokine-induced ligand for L-selectin is expressed
by cultured human umbilical vein endothelial cells (HU-
VEC) and microvascular endothelial cells (26–29). The
ligand is not CD34, and cultured HUVEC do not express
PSGL-1 or MAdCAM-1 (30, 31). L-selectin binding to
HUVEC is sialic acid–dependent (26), but is resistant to
cell treatment with 
 
O
 
-sialoglycoprotease (OSGE) (30), an
endopeptidase specific for glycoproteins containing closely
spaced O-linked sialic acid residues. Vascular endothelial
cells express sulfotransferases that may contribute to L-selec-
tin ligand generation (32). Cultured HUVEC also express
sialyltransferases and fucosyltransferases, and upregulate fu-
cosyltransferase activity after cytokine activation (33). Like-
wise, inflammation induces increased expression of 2H5
mAb–defined determinants on vascular endothelium (21).
Thus, it is possible that L-selectin ligands expressed on vas-
cular endothelium are sLe
 
x
 
-like determinants displayed by
OSGE-resistant cell surface molecules that are distinct from
the MECA-79 mAb–defined peripheral node addressins.
Therefore, functional L-selectin ligands expressed by hu-
man vascular endothelium were further characterized in
this study using HUVEC, an endothelial cell line derived
from HUVEC, EA.hy926 (926 cells), and 926 cells trans-
fected with human Fuc-TVII cDNA (926-FtVII cells). 926
cells maintain most of the characteristics of primary HU-
VEC (34, 35). These studies revealed that the CLA deter-
minant appears to be a critical component of the L-selectin
ligand that mediates lymphocyte tethering and rolling on
activated vascular endothelium.
 
Materials and Methods
 
L-selectin–IgM Fusion Protein.
 
A human L-selectin–mouse IgM
fusion protein (L
 
9
 
IgM) was generated by fusing cDNAs encoding
the extracellular domains of human L-selectin with the CH2-
CH4 domains of mouse 
 
m
 
 heavy chain. The L-selectin cDNA
contained a membrane-proximal seven amino acid deletion,
 
D
 
K-S, which prevents endoproteolytic cleavage as described (36).
The L-selectin–IgM cDNA was used to transiently transfect COS
cells by the DEAE-dextran method. After 1 wk, the culture su-
pernatant fluid was concentrated by ultrafiltration (membrane
XM300; Amicon Inc.) and L
 
9
 
IgM concentrations were measured
by ELISA as described (37).
 
Antibodies.
 
The anti–L-selectin (LAM1-3 and LAM1-14) mAbs
were made as described (38, 39). The HECA-452 (anti-CLA),
CSLEX-1 (anti-sLe
 
x
 
), and MECA-79 hybridomas were obtained
from the American Type Culture Collection. The anti–PSGL-1
(PL-1; Dr. Kevin Moore, University of Oklahoma Health Science
Center, Oklahoma City, OK), CD57 (HNK-1; Dr. Max Cooper,
University of Alabama in Birmingham, Birmingham, AL), anti–
P-selectin (G1; Dr. Bruce Furie, Beth Israel Medical Center,
Boston, MA), anti-VAP1 (TK8-14; Dr. Shirpa Jalkanen, Univer-
sity of Turku, FIN-20520 Turku, Finland) mAbs were gifts. The
mouse mAbs to E-selectin (HAE-1f), VCAM-1 (HAE-2d),
ICAM-1 (HAE-4b), and CD20 (HB13b) were produced as de-
scribed (26, 40). The anti-CD34 (My10; Becton Dickinson),
anti–mouse CD25 mAb (rat IgM; Southern Biotechnology Asso-
ciates), FITC-conjugated goat anti–rat IgM and anti–mouse IgM
antibodies (Southern Biotechnology Associates), and FITC-con-
jugated goat anti–mouse IgG (CALTAG Laboratories) were ob-
tained commercially.
 
Cell Lines and Lymphocyte Isolation.
 
926 cells were a gift from
Dr. Cora-Jean Edgell (University of North Carolina at Chapel Hill,
Chapel Hill, NC). 926 cells expressing 
 
a
 
1,3 fucosyltransferase
(926-FtVII) were generated by transfecting 926 cells with Fuc-
TVII cDNA (from Dr. Brent Weston, University of North
Carolina at Chapel Hill). Experiments were carried out using ei-
ther two different uncloned polyclonal populations of 926-FtVII
cells, lines of HECA-452
 
1
 
926-FtVII cells cloned from these pa-
rental populations of transfected cells, or oligoclonal populations
of HECA-452
 
1
 
 bright cells isolated by fluorescence-based cell
sorting. Similar, if not identical, immunofluorescence staining
and cell-binding results were obtained with each cell population.
COS cells were similarly transfected with Fuc-TVII cDNA with
subsequent selection of clonal transfected cell lines.
Heparinized blood of normal volunteers was isolated using
protocols approved by the Human Use Committee of Duke
University (Durham, NC). PBLs were isolated by density gradient
centrifugation using Lymphoprep (Nycomed Pharma As). HU-
VEC were isolated and cultured as described (26). In some exper-
iments 926-FtVII cells or HUVEC were incubated with OSGE
(80 and 160 
 
m
 
g/ml, respectively; Accurate Chemical and Scien-
tific Corp.) or 
 
Vibrio cholerae
 
 neuraminidase (0.1 U/ml; Calbio-
chem) in HBSS with Ca
 
2
 
1
 
 and 10 mM Hepes buffer for 1 h at
37
 
8
 
C before the adhesion assays were carried out. To reduce pro-
tein sulfation, 926-FtVII cells and HUVEC were grown in me-
dium containing 10 mM NaClO
 
3
 
 (Sigma Chemical Co.) for 24 h
before functional assays. HL-60 cells and the mouse pre-B cell
line, 300.19, were cultured as described (8). 300.19 cells trans-
fected with a nonshedding form of L-selectin (L
 
D
 
M-N) were
generated as described (36) and are termed 300.19-L
 
9
 
.
 
Immunofluorescence Staining and Flow Cytometry Analysis.
 
Lym-
phocytes or single-cell suspensions of 926 cells, HUVEC, or
COS-FtVII cells were washed twice, and 10
 
6
 
 cells were incu-
bated with primary antibodies diluted to optimal concentrations
for immunostaining on ice for 30–40 min. After washing, sec-
ondary antibody diluted to the appropriate concentration for op- 
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timal staining was added to the cells for 30 min. The cells were
washed and immunofluorescent staining was analyzed on a FAC-
Scan
 
®
 
 flow cytometer (Becton Dickinson). For staining with the
L
 
9
 
IgM fusion protein, 10
 
6
 
 cells were incubated with L
 
9
 
IgM (10
 
m
 
g/ml) for 40 min on ice, then diluted FITC-conjugated goat
anti–mouse IgM antibody was added for 40 min, followed by ad-
dition of PBS-2% Nu-serum for immediate analysis by flow cy-
tometry.
 
Nonstatic Cell Binding Assays.
 
An in vitro adhesion assay similar
to the Stamper-Woodruff frozen section assay (41) was used as de-
scribed (8, 26). 926 cells and 926-FtVII cells were cultured overnight
on glass microscope slides. In some experiments, COS or COS-
FtVII cells were transiently transfected with PSGL-1 (pPL85, from
Dr. Dale Cumming, Genetics Institute, Cambridge, MA) or CD34
(from Dr. Daniel Tenen, Beth Israel-Deaconess Hospital, Boston,
MA) cDNAs using the DEAE-dextran method as described (8).
24 h later, transfected COS or COS-FtVII cells were transferred
onto glass slides and were cultured overnight to between 25 and
50% confluence. Lymphocytes or 300.19 cells were washed twice
in cold DMEM with high glucose plus 5% FCS and then resus-
pended in the same medium. In mAb blocking experiments, cells
were preincubated in 200 
 
m
 
l medium with or without the appro-
priate mAb for 20 min on ice before the binding assays were ini-
tiated. Lymphocytes or 300.19 cells were added (10
 
6
 
 in 200 
 
m
 
l) to
the slides with horizontal rotation (64 rpm) at 4
 
8
 
C. After 30 min,
the medium was tipped off the slide, and the slides were placed
vertically in fixative (PBS, 2.4% [vol/vol] glutaraldehyde, pH 7.4)
overnight at 4
 
8
 
C. The slides were evaluated by phase-contrast
microscopy, and representative fields were photographed (final
magnification: 
 
3
 
400). The number of adherent cells was counted
for at least 10 random microscopic fields (0.16 mm
 
2
 
) on each of
three slides.
For assessing lymphocyte interactions with HUVEC, endothe-
lial cells were grown to 50% confluence on 0.1% gelatin-coated
glass slides and were stimulated with 100 U/ml of recombinant
human TNF-
 
a
 
 (Genzyme Corp.) for 6 h. Lymphocytes (10
 
6
 
 in
200 
 
m
 
l) resuspended in M199 medium containing 20% FCS were
overlayered onto each washed slide. Subconfluent monolayers of
HUVEC were used in these assays to allow accurate determina-
tions of the numbers of leukocytes bound with similar results ob-
tained when confluent monolayers of HUVEC were used. The
use of subconfluent endothelial cell monolayers did not promote
leukocyte binding due to matrix interactions under rotation, as
the leukocytes did not bind to spaces between HUVEC. Non-
static binding assays were carried out as above.
 
Endothelial–Leukocyte Adhesion Under Defined Flow Conditions.
 
Lymphocyte–endothelial cell interactions under physiologic flow
conditions were assessed using an in vitro flow chamber as described
(42). 926 or 926-FtVII cells grown to confluence on glass coverslips
were placed in a parallel-plate flow chamber. Lymphocytes (10
 
6
 
cells/ml) resuspended in PBS containing 0.75 mM CaCl
 
2
 
, 0.75 mM
MgCl
 
2
 
, and 0.5% (wt/vol) BSA were perfused through the cham-
ber for 10 min at a calculated shear stress of 1.85 dyn/cm
 
2
 
 via a sy-
ringe pump (Harvard Apparatus). Lymphocyte–endothelial interac-
tions were videotaped using an inverted phase-contrast microscope
with 10
 
3
 
 or 40
 
3
 
 objective power (Olympus Corp.) and a CCD
video camera (Hitachi Denshi, Ltd.). After a 10-min perfusion
period, multiple fields were videotaped for at least 30 s each over
the next 4 min of perfusion. In some cases, composite digitized im-
ages of single video tape frames were generated using commercial
software (Optimus version 5.0; Optimus Inc.) with contrast and
brightness optimized using Adobe Photoshop (Adobe Systems).
Rolling velocities were measured by determining the average
 
time it took 100 lymphocytes to roll a 400-
 
m
 
m distance over the
endothelial cell monolayer in multiple fields for each experiment.
Rolling lymphocyte numbers represent the number of rolling
lymphocytes that crossed a 400-
 
m
 
m line over a 10-s time period
in at least 10 random fields for each experiment.
 
RNA Isolation and PCR Amplification.
 
Total cellular RNA iso-
lated from cell pellets of 926-FtVII cells and HUVEC was used
for cDNA synthesis as described (43). PCR amplification of Fuc-
TVII cDNA used sense 5
 
9
 
-TCA GCC ACC TCC GAG GCA
TCT TCA ACT G-3
 
9
 
, and antisense 5
 
9
 
-CGT TGG TAT CGG
CTC TCA TTC ATG CCA GTG A-3
 
9
 
 primers to amplify a
500-bp fragment. PCR amplification was carried out at 94
 
8
 
C for
5 min, then 30 cycles of 94
 
8
 
C for 1 min, 66
 
8
 
C for 1 min, 72
 
8
 
C
for 1 min, followed by 72
 
8
 
C for 5 min. Primers for actin were
sense 5
 
9
 
-ATG TTT GAG ACC TTC AAC AC-3
 
9
 
, and antisense
5
 
9
 
-CAC GTC ACA CTT CAT GAT GG-3
 
9
 
, which generate a
495-bp fragment with PCR amplification as follows: 94
 
8
 
C for
5 min, then 30 cycles of 94
 
8
 
C for 1.5 min, 55
 
8
 
C for 2 min, 72
 
8
 
C
for 1 min; followed by 72
 
8
 
C for 5 min. The PCR products were
electrophoresed, transferred to nitrocellulose, and then hybrid-
ized with radiolabeled Fuc-TVII cDNA probe. Blots were ex-
posed to x-Omat AR film (Kodak) or quantified using a Storm
680 PhosphorImager (Molecular Dynamics).
For semiquantitative analysis of Fuc-TVII mRNA levels,
cDNA generated as described above was diluted over a broad
range of concentrations (neat to 1:5,000). The relative intensity
of Fuc-TVII and actin PCR bands generated from each cDNA
aliquot was then determined by gel analysis to generate dose–
response curves. The intensity of PCR products at a dilution of
1:50 to 1:100 was in the midpoint of the linear range where band
intensity was proportional to the amount of input cDNA. For
HUVEC, this translated into 
 
z
 
4 
 
3
 
 10
 
5
 
 starting cell equivalents for
cDNA synthesis and Fuc-TVII amplification, and 
 
z
 
2 
 
3
 
 10
 
5
 
 start-
ing cell equivalents for actin cDNA synthesis and amplification.
 
Statistical Analysis.
 
Data are expressed as means 
 
6
 
 SEM un-
less indicated otherwise. The Student’s 
 
t
 
 test was used to deter-
mine the significance of differences in sample population means.
 
Results
 
Vascular Endothelial Cells Express L-selectin Ligands.
 
L-selec-
tin ligands expressed on vascular endothelium were charac-
terized using the chimeric fusion protein, L
 
9
 
IgM, a method
originally described by others (7). Immunofluorescent
staining of HUVEC-derived 926 cells demonstrated low
levels of L
 
9
 
IgM reactivity that were inhibited to back-
ground staining levels by the presence of EDTA (Fig. 1, top).
Treatment of 926 cells with cytokines or agents previously
shown to induce L-selectin ligands on endothelial cells (26)
did not affect L
 
9
 
IgM reactivity (data not shown). 926 cells
stably transfected with a cDNA encoding Fuc-TVII (926-
FtVII) reacted more intensely with L
 
9
 
IgM than untrans-
fected 926 cells (Fig. 1, middle). L
 
9
 
IgM binding to 926-
FtVII cells was completely inhibited by EDTA (Fig. 1,
middle) and was decreased by 65–76% in the presence of
the LAM1-3 mAb, which blocks L-selectin function (Fig.
1, bottom). Therefore, 926 endothelial cells express L-selec-
tin ligands which are augmented by increasing Fuc-TVII
expression.
 
Lymphocyte–Endothelial Interactions Are Mediated by L-selec-
tin and Its Ligands.
 
Whether L-selectin ligands expressed 
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on 926-FtVII cells were functionally active was assessed us-
ing 300.19-L
 
9
 
. In a nonstatic cell binding assay developed to
assess leukocyte–endothelial cell interactions (26), 300.19-
L
 
9
 
 cells bound to 926-FtVII cells at significant levels (15.6 
 
6
 
0.9 cells/0.16-mm
 
2
 
 field; 
 
P
 
 
 
, 0.001), whereas 300.19 cells
did not bind (0.3 6 0.1 cells/field; Fig. 2 A). Furthermore,
human lymphocytes bound to 926-FtVII cells at significant
levels but did not bind to 926 cells (Fig. 2, B and C). Lym-
phocyte binding to 926-FtVII cells was blocked by lym-
phocyte pretreatment with the LAM1-3 mAb (99%), but
not by the non–function-blocking LAM1-14 mAb (Fig. 2,
B and C). Thus, lymphocyte interactions with 926-FtVII
cells were mediated specifically by L-selectin binding its
endothelial ligands.
L-selectin also mediated lymphocyte binding to 926-
FtVII cells under in vitro conditions of physiologic shear
flow. High numbers of lymphocytes attached to 926-FtVII
cell monolayers at a shear force of 1.85 dyn/cm2 and rolled
at velocities as slow as 100 mm/s, which were significantly
lower than the theoretical velocity of a lymphocyte not in-
teracting with the endothelial cell surface (526 mm/s) (44).
Mean rolling velocity at this shear force was 226 6 77 mm/s
(6 SD, n 5 200, Fig. 3 A). As expected for a totally L-selec-
tin–dependent adhesive interaction, 926-FtVII cells sup-
ported significant L-selectin–dependent rolling at shear
stresses between 0.75 and 3.0 dyn/cm2 with maximal roll-
ing between 1 and 2 dyn/cm2 as described (45). In addi-
tion, lymphocytes rolled into the field of view, indicating
that cells had attached upstream of the field under observa-
tion. The majority of lymphocytes in contact with 926-
Figure 1. L-selectin binds
ligands expressed on (top) 926
and (middle) 926-FtVII cells.
Cells were stained in indirect
immunofluorescence assays with
L9IgM (10 mg/ml) and FITC-
labeled goat anti–mouse IgM an-
tibody, and analyzed by flow
cytometry. (Bottom) 926-FtVII
cells were stained with L9IgM (10
mg/ml) that was preincubated
with a function-blocking anti–
L-selectin mAb (LAM1-3, 50
mg/ml) for 20 min. The dotted
lines represent background stain-
ing with an unreactive mouse
IgM antibody (HB13b, 10 mg/ml),
with secondary antibody alone,
or with L9IgM in the presence of
5 mM EDTA. Results represent
those obtained in three experi-
ments and with two independent
lines of 926-FtVII cells.
Figure 2. Lymphocyte binding to 926-FtVII cells in a nonstatic
binding assay at 48C is mediated by L-selectin. (A) Binding of
300.19 or 300.19-L9 cells (round cells) to 50% confluent mono-
layers of 926-FtVII endothelial cells (elongated cells). 3400. (B)
Human lymphocyte (PBL, round cells) binding to 926 and 926-
FtVII cells in the presence of medium, LAM1-3 mAb (50 mg/ml),
or an isotype-matched, nonblocking mAb, LAM1-14 (50 mg/ml).
Similar results were obtained when the lymphocytes were pre-
treated with the mAb and washed before being added to the 926
cells, or if the lymphocyte suspension pretreated with mAb was
added directly to the assay for a final twofold dilution of mAb.
3400. (C) Values represent the mean (6 SEM) number of lym-
phocytes bound in at least 30 0.16-mm2 fields from the experi-
ment depicted in B. Results represent those obtained in three ex-
periments.245 Tu et al.
FtVII monolayer remained in contact for their entire transit
across the field of view, although there was no stationary
adhesion of lymphocytes to 926-FtVII cell monolayers. By
contrast, lymphocytes did not interact with untransfected
926 monolayers at detectable levels (Fig. 3 B). Preincuba-
tion of lymphocytes with the LAM1-3 mAb reduced the
frequency of rolling lymphocytes by 94–97%, whereas the
LAM1-14 mAb had no effect (Fig. 3 B). Thus, lymphocyte
tethering and rolling on 926-FtVII cells is mediated by
L-selectin interacting with its endothelial ligands.
926-FtVII Cells Express the CLA and sLex Antigens.
The expression of L-selectin ligands by 926 and 926-FtVII
cells was assessed using a panel of mAbs reactive with char-
acterized adhesion molecules. 926-FtVII cells expressed
sLex antigens at high levels as defined by both the CSLEX-1
and HECA-452 mAbs (Fig. 4 A). Untransfected 926 cells
expressed HECA-452–defined epitopes at low levels, but it
was not possible to detect CSLEX-1 mAb–defined antigen
(Fig. 4 A). 926 and 926-FtVII cells did not express detect-
able levels of the antigens identified by the MECA-79 or
HNK-1 mAbs and did not express detectable levels of
P-selectin, E-selectin, CD34, PSGL-1, VCAM-1, VAP-1,
or ICAM-1 as described previously in some cases (46, 47).
The virtual absence or low expression of adhesion mole-
cules other than L-selectin ligands may explain the rela-
tively fast rolling velocities of leukocytes on 926-FtVII cells
and is consistent with the complete deficit in lymphocyte
firm adhesion on 926-FtVII cells during in vitro flow
chamber assays. Consistent with this observation, a lack of
P-selectin expression in vivo increases leukocyte rolling
from  z49 mm/s in wild-type mice to z129 mm/s in P-selec-
tin–deficient mice under conditions where L-selectin pre-
dominantly mediates rolling (48). In addition, ICAM-1 de-
ficiency also results in leukocytes rolling at faster velocities
in vivo (49). Therefore, increased sLex and CLA expressions
were the only detectable differences between 926 and 926-
FtVII cells.
CLA Is the L-selectin Ligand on Vascular Endothelium.
Whether or not sLex expression contributed to lymphocyte
attachment on 926-FtVII cells was assessed using the
HECA-452 and CSLEX-1 mAbs. Preincubation of 926-
FtVII cells with the HECA-452 mAb blocked most lym-
phocyte attachment (94–95%; P  , 0.001), whereas the
CSLEX-1 mAb did not significantly inhibit lymphocyte
binding in the nonstatic binding assay (Fig. 4 B). Pretreat-
ment of lymphocytes with the HECA-452 mAb before the
binding assay did not significantly affect lymphocyte bind-
ing to 926-FtVII cells (Fig. 4 B). Under defined shear flow
conditions using a parallel-plate flow chamber, preincuba-
tion of 926-FtVII cells with the HECA-452 mAb signifi-
cantly (.90%) reduced the number of lymphocytes rolling
at 1.85 dyn/cm2 of shear stress (Fig. 3 B). By contrast, the
CSLEX-1 mAb did not inhibit lymphocyte rolling. Thus,
the CLA subset of sLex antigens is a critical component of
the L-selectin ligands expressed on 926-FtVII cells.
Sialylation and Sulfation Are Important Features of Vascular
L-selectin Ligands. Whether sialylation or sulfation influ-
enced L-selectin–mediated lymphocyte attachment to 926-
FtVII cells was assessed. Pretreatment of 926-FtVII cells
with neuraminidase abolished (.98% decrease) lympho-
cyte attachment to 926-FtVII cells in both nonstatic bind-
ing assays (Fig. 5 A) and under defined flow conditions
(Fig. 5 B). Similarly, culturing 926-FtVII cells in the pres-
ence of sodium chlorate (NaClO3) for 24 h significantly in-
Figure 3. L-selectin mediates lymphocyte tethering and rolling under
physiologic shear flow through CLA expressed by 926-FtVII cells. (A)
Representative lymphocyte rolling on 926-FtVII monolayers in a paral-
lel-plate flow chamber (340 objective) at a shear force of 1.85 dyn/cm2.
Single frames of video tape at 0.4-s intervals were digitized to generate a
composite image of a rolling lymphocyte (arrowheads). Flow is from left
to right. Bar, 20 mm. (B) Numbers of lymphocytes rolling across mono-
layers of 926 or 926-FtVII cells. Lymphocytes preincubated with either medium, the LAM1-3, or LAM1-14 mAbs (50 mg/ml) for 20 min were diluted
fivefold and perfused through the flow chamber. 926 or 926-FtVII cells grown on slides were overlayered with medium alone, or containing the HECA-
452 (HECA, 10 mg/ml) or CSLEX-1 (CSLEX, 50 mg/ml) mAbs for 20 min immediately before the assays. Values represent the mean (6 SEM) number
of rolling lymphocytes that entered a 400-mm-wide field over a 10-s time period in 10 randomly chosen fields near the centerline of the flow chamber
after a 10-min time period. Results represent those obtained in three experiments, except for HECA and CSLEX results, which represent two experi-
ments.246 CLA Is a Critical Component of Vascular L-selectin Ligands
hibited (74–84%) lymphocyte attachment in nonstatic
binding assays (Fig. 5 A). Although L-selectin binds to sev-
eral mucin-like proteins that are sensitive to endoproteolytic
cleavage by OSGE, treatment of 926-FtVII cells with
OSGE did not significantly affect lymphocyte attachment
in the nonstatic binding assays (Fig. 5 A) or under physio-
logic flow conditions (Fig. 5 B). In parallel control assays
with HL-60 cells, OSGE treatment completely removed
the PL-1 mAb–defined epitope from PSGL-1 (data not
shown). Thus, sialic acid and sulfate are essential com-
ponents of the L-selectin ligands expressed on vascular en-
dothelium even though the ligands on vascular endothe-
lium are OSGE-resistant.
HUVEC Activation Induces L-selectin Ligands. Whether
L-selectin ligands expressed by HUVEC were CLA-depen-
dent was assessed using TNF-activated HUVEC. The
L9IgM fusion protein reacted weakly with resting HUVEC
but was bound at fourfold higher levels after TNF-a acti-
vation (Fig. 6 A). L9IgM binding peaked between 4 and 6 h
of HUVEC activation and was sustained at high levels for
at least 24 h. At each time point, L9IgM reactivity was re-
duced to background staining levels in the absence of Ca21.
Similar results were obtained when HUVEC were stained
with the HECA-452 mAb; low levels of CLA expression
by resting HUVEC with expression significantly increased
(100–200%) 6 h after TNF-a activation (Fig. 6 B). In addi-
tion, resting HUVEC expressed Fuc-TVII transcripts and
relative Fuc-TVII mRNA levels increased 1.8–2.0-fold
(n 5 2) after TNF-a activation for 6 h (Fig. 6 C). 926 cells
also expressed Fuc-TVII mRNA, but at levels significantly
below those of 926-FtVII cells (data not shown). Therefore,
the time course of increased L9IgM and HECA-452 staining
correlated with the previously described induction of func-
tional L-selectin ligands after HUVEC activation (26).
Increased CLA expression by TNF-a–activated HU-
VEC correlated with lymphocyte binding. In nonstatic
binding assays, TNF-a activation of HUVEC induced sig-
nificant lymphocyte binding, whereas resting HUVEC
supported minimal binding (Fig. 6 D). The LAM1-3 mAb
inhibited lymphocyte binding to activated HUVEC by 65–
76%, while the non–function-blocking LAM1-14 mAb did
not affect lymphocyte binding (Fig. 6 D). Treatment of ac-
tivated HUVEC with the HECA-452 mAb reduced lym-
phocyte binding by 53–71%. Pretreatment of activated
HUVEC with neuraminidase reduced lymphocyte binding
by 46–55%. HUVEC cultured in the presence of 10 mM
NaClO3 for 24 h, with TNF-a added during the last 6 h of
culture, also significantly inhibited (31–40%) lymphocyte
binding. By contrast, OSGE treatment of cytokine-acti-
vated HUVEC did not significantly affect lymphocyte
binding as previously reported (30). Thus, lymphocyte
binding to activated HUVEC through L-selectin required
interactions with a sulfated, CLA-bearing ligand.
CLA Expression Alone Is Insufficient for L-selectin Binding.
Whether CLA expression alone was sufficient to generate
L-selectin ligands was assessed using COS cells stably trans-
fected with Fuc-TVII cDNA. COS cells did not express
the HECA-452 antigen, although COS-FtVII cells ex-
pressed CLA at levels comparable to those observed on
926-FtVII cells (Fig. 4 A and Fig. 7 A). In sharp contrast
with 926-FtVII cells, COS-FtVII cells did not bind lym-
phocytes or 300.19-L9 cells in nonstatic binding assays (Fig.
7, B and C). To assess whether a specific protein backbone
was required for CLA presentation, COS-FtVII cells were
transiently transfected with cDNAs encoding either PSGL-1
or CD34. COS-FtVII cells expressed these cell surface anti-
gens at high levels (Fig. 7 A). COS-FtVII cells expressing
PSGL-1 bound both lymphocytes and 300.19-L9 cells at
high levels (Fig. 7, B and C). By contrast, COS-FtVII cells
expressing CD34 did not bind either lymphocytes or
300.19-L9 cells above background levels under these assay
conditions. These results demonstrate that CLA may require
a specific protein scaffold to serve as an L-selectin ligand, in
addition to a requirement for appropriate sulfation.
Figure 4. CLA mediates lymphocyte binding to 926-FtVII cells. (A)
Staining of 926 and 926-FtVII cells with the HECA-452 (10 mg/ml) or
CSLEX-1 (20 mg/ml) mAbs (bold lines) in indirect immunofluorescence
assays with flow cytometry analysis. Dashed lines represent cell staining
with equivalent amounts of unreactive isotype-matched control antibodies
or with secondary antibody alone. (B) Lymphocyte (PBL) binding to 926-
FtVII cells assessed in a nonstatic binding assay. 926-FtVII cells were prein-
cubated with medium alone or with medium containing the HECA-452
(10 mg/ml) or CSLEX-1 (50 mg/ml) mAbs for 20 min. Lymphocytes
were also incubated in medium or medium containing the HECA-452
mAb (10 mg/ml) for 20 min, and then overlayered onto z50% confluent
monolayers of 926-FtVII cells at 48C with rotation. Values represent the
mean (6 SEM) number of lymphocytes bound in at least 30 0.16-mm2
fields. Results represent those obtained in at least two experiments.247 Tu et al.
Discussion
In this study, it was found that (a) transfection of a vascular
endothelial cell line with Fuc-VII cDNA induced the expres-
sion of functional L-selectin ligands (Figs. 1–3); (b) vascular
endothelial cells with increased Fuc-TVII expression showed
significant sLex staining as defined by the HECA-452 (CLA)
and CSLEX-1 mAbs (Fig. 4), but not MECA-79 mAb stain-
ing (data not shown); (c) HUVEC activation upregulated
functional L-selectin ligand expression, Fuc-TVII transcrip-
tion, and CLA expression (Fig. 6); (d) pretreatment of en-
dothelial monolayers with the HECA-452 mAb, but not
the CSLEX-1 mAb, blocked L-selectin–dependent lym-
phocyte attachment and adhesion to vascular endothelium
(Figs. 3, 4, and 6); (e) the L-selectin ligands on vascular en-
dothelium were a novel class of ligands that required sulfa-
tion and sialylation, but were OSGE-resistant, which dis-
tinguishes them from CD34 and PSGL-1 (Fig. 5); and (f)
CLA requires appropriate presentation on the cell surface
to serve as an L-selectin ligand (Fig. 7). These findings
demonstrate that the HECA-452 subset of sLex antigens
defines an essential component of the inducible vascular
L-selectin ligand.
CLA, as defined by the HECA-452 mAb, is a carbohy-
drate determinant specifically expressed by HEV within
lymphoid organs, by monocyte subsets and small numbers
of leukocytes in tonsils and lymph nodes, and by endothe-
lium at sites of long-standing chronic inflammation (50).
However, most noted is that the HECA-452 antigen iden-
tifies a population of skin-homing memory T cells which
bind E-selectin displayed by dermal endothelium (23, 24,
51, 52). Although the induction of CLA expression within
vessels of inflamed tissues also closely correlates with in-
tense local infiltration of lymphocytes, a role for CLA as an
L-selectin ligand was initially discounted since saturating
HEV with the HECA-452 mAb did not inhibit lympho-
cyte binding (50). However, our finding that preincubation
of endothelial cells with the HECA-452 mAb blocked L-selec-
tin–mediated binding of leukocytes to non-HEV vascular
endothelium (Figs. 3, 4, and 6) clearly demonstrates that
CLA is a major component of the vascular L-selectin
ligand. In addition, recent studies have shown that the
HECA-452 mAb can bind sulfo sLex determinant(s) which
may serve as L-selectin ligands on HEV (12, 20) and rat en-
dothelium at sites of inflammation (21). Since HEV-like
vessels that support lymphocyte migration are observed in
chronically inflamed nonlymphoid tissues, the current stud-
ies suggest that a subset of CLA determinants induced on
vascular endothelial cells functions as L-selectin ligands.
Although CLA was an essential component of the vascu-
lar L-selectin ligand, CLA expression alone was not suffi-
cient for L-selectin binding. Sulfation was also required
since NaClO3 treatment of 926-FtVII cells (Fig. 5 A) and
activated HUVEC (Fig. 6 D) abrogated L-selectin–depen-
dent attachment. In addition, vascular endothelial cells may
be required to display CLA on specialized glycoprotein
scaffolds (Fig. 7). This tripartite requirement for L-selectin
ligand components may explain why 926-FtVII cells ap-
peared to express CLA at high levels, but bound lower lev-
els of L9IgM fusion protein (Figs. 1 and 4). Thus, L-selectin
may only bind a subset of CLA that is appropriately sulfated
or displayed by appropriate sulfated scaffolds. Similarly, ac-
tivated HUVEC bound L9IgM well, yet HECA-452 stain-
ing was not dramatically increased after activation (Fig. 6, A
and B). Thus, CLA expression on HUVEC may be re-
stricted to a subset of cell surface structures that efficiently
function as L-selectin ligands. Additionally, L-selectin may
bind different vascular ligands with differing affinities. It is
possible that the L9IgM fusion protein binds low-affinity
L-selectin ligands which are unable to support cell rolling
but are visualized during immunofluorescence staining ex-
periments with the pentameric L9IgM fusion protein.
There may also be a sharp threshold for ligand expression
levels required for L-selectin–mediated attachment or roll-
Figure 5. L-selectin ligands on vascu-
lar endothelium require sialylation and
sulfation. (A) Lymphocyte (PBL) bind-
ing to z50% confluent 926-FtVII cell
monolayers was assessed in a nonstatic
binding assay. 926-FtVII cells grown on
glass coverslips were pretreated with
medium alone, neuraminidase (Neur.),
OSGE, or NaClO3 as indicated. Values
represent the mean (6 SEM) number of
lymphocytes bound in at least 30 micro-
scopic fields. (B) Lymphocyte (PBL) roll-
ing on confluent monolayers of 926 or
926-FtVII cells was assessed in a parallel-
plate flow chamber at a shear force of
1.85 dyn/cm2. 926-FtVII cells were
pretreated with medium, neuraminidase
(Neur.), or OSGE as indicated. Values
represent the mean (6 SEM) number of
rolling lymphocytes that entered a 400-
mm-wide field over a 10-s time period
in 10 randomly chosen fields near the centerline of the flow chamber after a 10-min time period. Results represent those obtained in at least three inde-
pendent experiments, except for OSGE treatment under shear flow, which was carried out twice.248 CLA Is a Critical Component of Vascular L-selectin Ligands
ing that could make large differences in leukocyte binding
to activated endothelium. Just two- to fivefold differences
in L-selectin expression levels dramatically affect L-selectin
binding activity for PSGL-1 in vitro and HEV in vivo (8,
53). Thus, upregulated expression of fucosyltransferases,
sulfotransferases, sialyltransferases, or protein scaffolds could
each contribute to the generation of functional L-selectin
ligands in vivo.
The protein backbone of the vascular L-selectin ligand may
be unknown. CLA displayed on PSGL-1 functions as the
dominant L-selectin ligand on leukocytes (Tu, L., P.G. Mur-
phy, and T.F. Tedder, manuscript in preparation), but PSGL-1
is not expressed by endothelial cells (31). CLA on endothelial
cells is also unlikely to be presented by GlyCAM-1,
sgp200, or CD34. GlyCAM-1 lacks a transmembrane do-
main and is likely to be a secretory product of HEV found
primarily in serum (54). The sgp200 HEV ligand may also
be a secreted protein like GlyCAM-1 (6, 55). CD34 is only
expressed by a small subset of HUVEC, is not upregulated
by cytokines, and is OSGE-sensitive, whereas the vascular
L-selectin ligand is OSGE-insensitive (Fig. 5, and reference
30). In addition, mice lacking CD34 are generally normal
(33). Therefore, it is tempting to speculate that L-selectin
will require or prefer CLA presentation by a specialized
glycoprotein. Endothelial L-selectin ligands may also vary
in differing vascular beds. For example, TNF induces L-selec-
tin ligands on cultured bovine aortic endothelial cells that
are not affected by neuraminidase treatment and appear to
Figure 6. Functional L-selectin ligand expression by cytokine-activated endothelial cells. HUVEC monolayers cultured with medium (0 h) or TNF-a
(100 U/ml) for the times indicated were stained in indirect immunofluorescence assays with (A) the L9IgM fusion protein (10 mg/ml) or (B) the HECA-
452 mAb (10 mg/ml), and subsequently analyzed by flow cytometry. Dashed lines represent background staining with an unreactive mouse IgM (HB13b,
10 mg/ml) or rat IgM (anti–mouse CD25, 20 mg/ml) antibody. Identical background staining was obtained when L9IgM staining was carried out in the
presence of 5 mM EDTA, with the CSLEX-1 mAb (20 mg/ml), or with secondary antibody alone. Results represent those obtained in three experi-
ments. (C) Fuc-TVII mRNA expression in resting and 6-h TNF-a–activated HUVEC. cDNA generated from z4 3 105 resting or TNF-a–activated
(6 h) HUVEC was amplified in semiquantitative PCR assays. An autoradiograph of the Southern blot probed with a 32P-labeled Fuc-TVII cDNA probe
is shown. The (-)RT lane represents PCR amplification of control samples without cDNA added. PCR amplification of HUVEC mRNA samples in
which the reverse transcriptase was omitted did not generate detectable bands (data not shown). Actin cDNA from z2 3 105 HUVEC was also PCR
amplified as a control. Results represent those obtained in two experiments. (D) CLA mediates lymphocyte binding to TNF-a–activated HUVEC. HU-
VEC monolayers at z50% confluence were cultured in medium alone or containing TNF-a (100 U/ml) for 6 h before pretreatment with medium, the
HECA-452 mAb (10 mg/ml), or neuraminidase (Neur.). Alternatively the cells were cultured previously with NaClO3 for 24 h. Lymphocytes (PBL)
were preincubated with either the LAM1-3 (50 mg/ml) or the LAM1-14 (50 mg/ml) mAbs for 20 min before being overlayered onto the HUVEC
monolayers with lymphocyte binding assessed in a nonstatic binding assay at 48C. Each mAb remained during the binding assay but was diluted by half.
Values represent the mean (6 SEM) of pooled numbers of bound lymphocytes in at least 60 randomly chosen microscopic fields obtained from at least
three independent experiments.249 Tu et al.
be related to heparan sulfate (29). Similarly, L-selectin
ligands identified on human cardiac microvascular endo-
thelial cells do not require sialic acid, but do require sulfa-
tion (56). Thus, the current studies will need to be ex-
tended to other vascular beds and the complete structure of
the L-selectin ligand will need to be further characterized.
L-selectin ligands on HEV of lymphoid tissues histori-
cally have been identified by the MECA-79 mAb, al-
though this antigen was not a component of the L-selectin
ligand on human vascular endothelium. The MECA-79
mAb identifies a specific sulfation-dependent epitope on
some carbohydrate side chains expressed by HEV (6, 15,
16, 19). These carbohydrates are also expressed on human
venular endothelium at cutaneous lesions and sites of chronic
inflammation (57, 58). The MECA-79 mAb blocks lympho-
cyte binding to murine peripheral lymph node HEV by
95% (15), and it inhibits lymphocyte migration into lymph
nodes in vivo by z80% (15, 59). However, in humans, the
MECA-79 mAb only partially inhibits (30–50%) lympho-
cyte binding to HEV of peripheral lymph nodes (58, 60).
In addition, OSGE-resistant L-selectin ligands distinct from
the MECA-79-subset of sLex antigens are expressed by hu-
man HEV (60), a finding consistent with the observation
that HEV of Fuc-TVII–deficient mice are unable to sup-
port L-selectin–mediated lymphocyte binding despite ex-
pressing the MECA-79 antigen at normal levels (18).
Therefore, it is possible that the CLA-bearing vascular
L-selectin ligand identified in this study may share func-
tional and structural characteristics with the OSGE-resistant
L-selectin ligands of HEV.
In summary, the current findings demonstrate that CLA
provides a key component in the expression of L-selectin
ligands on vascular endothelium that initiate leukocyte
tethering and rolling. The association of CLA with the re-
cruitment of lymphocytes to sites of inflammation in the
skin (50) is consistent with a demonstrated role for L-selec-
tin in mediating leukocyte migration to the skin during
contact hypersensitivity responses and after allogeneic skin
transplantation (61, 62). Moreover, CLA is expressed by
vessels with the morphologic appearance of HEV in areas
of extensive lymphoid infiltration in autoimmune thyroid-
itis, Graves and Hashimoto’s disease, and in the gut of pa-
tients with Crohn’s disease (50). Since the generation of
CLA correlates with Fuc-TVII enzymatic activity and re-
quires sulfation, this offers two potential sites for therapeu-
tic regulation of L-selectin ligand expression during vascu-
lar inflammation.
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Figure 7. CLA expression alone is insufficient for L-selectin binding.
(A) Staining of COS and COS-FtVII cells with the HECA-452 (10 mg/
ml), PL-1 (anti–PSGL-1, 10 mg/ml), and My10 (anti-CD34, 10 mg/ml)
mAbs in indirect immunofluorescence assays with flow cytometry analy-
sis. Dashed lines represent cell staining with equivalent amounts of unre-
active, isotype-matched control antibodies or with secondary antibody
alone. (B) Binding of lymphocytes (PBLs) to COS or COS-FtVII cells
transiently transfected with cDNAs encoding PSGL-1 or CD34 in a non-
static binding assay. (C) Binding of 300.19 or 300.19-L9 cells to COS or
COS-FtVII cells transiently transfected with cDNAs encoding PSGL-1 or
CD34 as indicated in a nonstatic binding assay. Values in B and C repre-
sent the mean (6 SEM) number of lymphocytes bound to COS cells in at
least 30 randomly chosen microscopic fields as previously described (8).
All results represent those obtained in three independent experiments.250 CLA Is a Critical Component of Vascular L-selectin Ligands
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